Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment

The correlation between improvement in longitudinal liver stiffness and fibrosis regression has not been properly evaluated during long-term antiviral therapy in chronic hepatitis B (CHB) patients. In this study, liver stiffness was serially performed by FibroScan ® every 26 weeks in a prospective c...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental medicine 2018-08, Vol.18 (3), p.433-443
Main Authors: Wu, Sheng-Di, Liu, Li-Li, Cheng, Ji-Lin, Liu, Yun, Cheng, Li-Sha, Wang, Si-Qi, Ma, Wei, Chen, Li-Ping, Tseng, Yu-Jen, Wang, Ji-Yao, Shen, Xi-Zhong, Jiang, Wei
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral drugs
Cirrhosis
Fibrosis
Hematology
Hepatitis
Hepatitis B
Internal Medicine
Liver
Liver cirrhosis
Medicine
Medicine & Public Health
Multivariate analysis
Oncology
Original Article
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The correlation between improvement in longitudinal liver stiffness and fibrosis regression has not been properly evaluated during long-term antiviral therapy in chronic hepatitis B (CHB) patients. In this study, liver stiffness was serially performed by FibroScan ® every 26 weeks in a prospective cohort of CHB patients receiving entecavir. Results were compared with liver biopsies at baseline and week 78. A total of 120 treatment-naïve CHB patients were analyzed, in which 54 (45%) patients had fibrosis regression at 78 weeks of antiviral therapy. Liver stiffness measurement presented as a rapid-to-slow decline pattern and decreased more significantly in patients with fibrosis regression than those without improvement in fibrosis at week 78 (− 46.4 vs. − 28.6%, P 
ISSN:1591-8890
1591-9528
DOI:10.1007/s10238-018-0501-x